- Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
-
Kim KK
- KMID: 2447082
- Korean J Fam Med.
- 2019 Mar;40(2):63-71.
- doi: 10.4082/kjfm.19.0013
The Korean Ministry of Food and Drug Safety has approved three anti-obesity drugs for long-term management in the past decade. In addition, since 2019, bariatric surgery has been financially supported... -
- CITED
-
- Close
- SHARE
-
- Close
- Mechanisms of action and clinical applications of anti-obesity drugs currently available in Korea
-
Kim KK
- KMID: 2462242
- J Korean Med Assoc.
- 2019 Nov;62(11):588-597.
- doi: 10.5124/jkma.2019.62.11.588
Over the last 5 years, the Korean Ministry of Food and Drug Safety has approved four anti-obesity drugs for long-term weight management. In this review, the mechanisms of action and... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues
-
Chun HJ, Kwon HS
- KMID: 2173920
- J Korean Diabetes.
- 2013 Sep;14(3):125-127.
- doi: 10.4093/jkd.2013.14.3.125
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety of Anti-Obesity Drugs Approved for Long-Term Use
-
Kim KK
- KMID: 2271148
- Korean J Obes.
- 2015 Mar;24(1):17-27.
- doi: 10.7570/kjo.2015.24.1.17
Because of the widespread use of ant-obesity medications, bariatricians need to be aware not only of common adverse events but also uncommon serious events in the pharmacotherapy of obesity. Safety... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications
-
Oh TJ
- KMID: 2459810
- J Obes Metab Syndr.
- 2019 Sep;28(3):158-166.
- doi: 10.7570/jomes.2019.28.3.158
Diabetes is prevalent in obese population, and obesity management is the first step in preventing diabetes. Traditionally, lifestyle modification including reduced-calorie diet, physical activity, and behavior intervention is the core... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in Anti-Obesity Agents
-
Kim MK, Kim CS
- KMID: 2438040
- Korean J Med.
- 2018 Dec;93(6):501-508.
- doi: 10.3904/kjm.2018.93.6.501
Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity,... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
-
Jeong IK
- KMID: 2416256
- J Lipid Atheroscler.
- 2018 Jun;7(1):32-41.
- doi: 10.12997/jla.2018.7.1.32
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
-
Lee I, Kang ES
- KMID: 2458964
- J Korean Diabetes.
- 2019 Sep;20(3):149-156.
- doi: 10.4093/jkd.2019.20.3.149
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances for Anti-Obesity Agents
-
Kim CS
- KMID: 2173852
- J Korean Diabetes.
- 2015 Dec;16(4):260-268.
- doi: 10.4093/jkd.2015.16.4.260
Obesity is one of the most significant risk factor for diabetes, cardiovascular disease, malignancy and other chronic diseases. The obesity and its associated conditions is one of the most urgent... -
- CITED
-
- Close
- SHARE
-
- Close
- New and emerging drugs for the treatment of obesity
-
Roh E, Kim MS
- KMID: 2195041
- J Korean Med Assoc.
- 2015 May;58(5):452-457.
- doi: 10.5124/jkma.2015.58.5.452
Obesity has become a global public health problem. The importance of obesity is highlighted by the fact that obesity-related comorbidities, such as type 2 diabetes, cardiovascular disease, and cancer, are... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
-
Kim GS, Park JH, Won JC
- KMID: 2450509
- Endocrinol Metab.
- 2019 Jun;34(2):106-116.
- doi: 10.3803/EnM.2019.34.2.106
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular... -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutics for Diabetes Using Incretin Hormone
-
Oh S
- KMID: 2259281
- Korean J Med.
- 2011 Jun;80(6):625-634.
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types: GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management
-
Jeon WS, Park CY
- KMID: 2384235
- Endocrinol Metab.
- 2014 Dec;29(4):410-417.
- doi: 10.3803/EnM.2014.29.4.410
Type 2 diabetes and obesity have a complex relationship; obesity is linked to insulin resistance, the precursor to type 2 diabetes. The management of obesity is an important method to... -
- CITED
-
- Close
- SHARE
-
- Close
- New Drugs for Obesity Treatment
-
Kim WJ, Lee CB
- KMID: 2268868
- Korean J Med.
- 2016 Feb;90(2):121-126.
- doi: 10.3904/kjm.2016.90.2.121
There have recently been many advances in obesity treatment, including lifestyle modifications and pharmacological and surgical treatments. Specifically, pharmacological strategies have improved significantly. However, the history of the development of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
-
Cho YM, Wideman RD, Kieffer TJ
- KMID: 2169303
- Endocrinol Metab.
- 2013 Dec;28(4):262-274.
- doi: 10.3803/EnM.2013.28.4.262
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which... -
- CITED
-
- Close
- SHARE
-
- Close
